RC 28 E
Alternative Names: RC-28-E; RC28-E injectionLatest Information Update: 06 Sep 2023
At a glance
- Originator RemeGen; Yantai Rongchang Biological Engineering
- Developer RemeGen
- Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Fibroblast growth factor inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Diabetic macular oedema; Wet age-related macular degeneration
- Phase II Diabetic retinopathy
Most Recent Events
- 31 Jul 2023 RemeGen completes a phase II trial for Diabetic macular oedema (In adults, In the elderly) (Intravitreous) (NCT04782115)
- 08 Jun 2023 Phase-III clinical trials in Diabetic macular oedema in China (Intravitreous) (NCT05885503)
- 05 Jun 2023 Adverse events data from a phase I trial in Wet age-related macular degeneration released by RemeGen